Skip to content
Terminus Peptides
Sign inContact
  • Research use only — not for human or veterinary use
  • 67 compound profiles, every source cited
  • 63 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Peptide analogue

Tirzepatide

Also known as GIP/GLP-1 receptor co-agonist, LY3298176

Clinical — evidence level 4 of 4: Established clinical evidencePrescription only — UK regulatory status: Prescription-only medicine (UK)

Overview

A synthetic dual agonist of the GIP and GLP-1 receptors. A prescription-only medicine in the UK.

Category
Peptide analogue
Highest evidence level identified
Established clinical evidence
Last scientifically reviewed
22 August 2026
Last regulatory review
22 August 2026

Mechanism under investigation

Tirzepatide is a 39-amino-acid synthetic peptide built on the GIP sequence, engineered to activate both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, and carrying a C20 fatty diacid moiety that binds albumin and extends its half-life to around five days. The discovery work characterises it as an imbalanced agonist — closer to native potency at the GIP receptor than at the GLP-1 receptor — which its developers argue contributes to the metabolic effects observed. Receptor activation increases glucose-dependent insulin secretion, slows gastric emptying and reduces food intake.

Research areas

  • Metabolic research
  • Incretin biology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

Well characterised. The discovery paper reports binding affinity and signalling at both human receptors, the deliberate imbalance between them, and the albumin-binding behaviour of the lipidated backbone.

Animal evidence

Studies in living non-human animals.

Extensive preclinical work in rodent and primate models is reported in and around the discovery programme, covering glucose control, body-weight reduction and receptor-knockout dissection of which receptor contributes what.

Human observational evidence

Studies observing people without assigning an intervention.

Present and growing rapidly since licensing, including large real-world cohort comparisons against GLP-1 receptor agonists. Observational findings so far track the trial results.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Extensive and of high quality. The SURPASS programme established glycaemic superiority over semaglutide 1 mg at all three tested doses in type 2 diabetes; SURMOUNT-1, in 2,539 adults with obesity, reported mean weight reductions up to around a fifth of body weight over 72 weeks. Gastrointestinal adverse events were the most common reason for discontinuation in both.

Study limitations

  • Nearly all pivotal trials were funded and run by the manufacturer, as is usual for a new medicine; independent replication is limited to real-world data.
  • Trial populations were selected and monitored; the safety picture outside those populations rests on pharmacovigilance rather than controlled data.
  • Weight regain after discontinuation is documented in the extension literature, and durability of effect without continued dosing is not established.
  • Head-to-head data against semaglutide at its highest licensed dose arrived later than the headline SURPASS-2 comparison against 1 mg, which is the figure most often quoted.

UK regulatory context

Prescription-only medicine (UK)

A medicine that may lawfully be supplied in the UK only against a prescription from an appropriate practitioner.

Source: Mounjaro KwikPen solution for injection in pre-filled pen — Summary of Product Characteristics (opens medicines.org.uk in a new tab) (electronic Medicines Compendium)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

Tirzepatide is a UK prescription-only medicine, prescribed with dose titration and clinical follow-up. Its recognised adverse effects in the trials were predominantly gastrointestinal — nausea, vomiting, diarrhoea — dose-dependent and occasionally treatment-limiting; pancreatitis and gallbladder disease appear in the product information as recognised risks. All of that safety picture belongs to the licensed products, manufactured to pharmaceutical standards and taken under supervision. It does not transfer to research-grade material, for which no human safety dataset exists.

References